The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant

Rimonabant is the first CB1 receptor inhibitor available in the Brazilian market. This new drug has been approved for the treatment of obese or overweight patients associated with cardiovascular risk factors. In this article it is compared the effects of rimonabant treatment in obese patients with c...

Descripción completa

Detalles Bibliográficos
Autor principal: Murro, Ada Letícia B
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770455/
https://www.ncbi.nlm.nih.gov/pubmed/19835615
http://dx.doi.org/10.1186/1758-5996-1-18
_version_ 1782173659593441280
author Murro, Ada Letícia B
author_facet Murro, Ada Letícia B
author_sort Murro, Ada Letícia B
collection PubMed
description Rimonabant is the first CB1 receptor inhibitor available in the Brazilian market. This new drug has been approved for the treatment of obese or overweight patients associated with cardiovascular risk factors. In this article it is compared the effects of rimonabant treatment in obese patients with cardiovascular risk factors to usual obesity pharmacological treatment.
format Text
id pubmed-2770455
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27704552009-10-30 The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant Murro, Ada Letícia B Diabetol Metab Syndr Review Rimonabant is the first CB1 receptor inhibitor available in the Brazilian market. This new drug has been approved for the treatment of obese or overweight patients associated with cardiovascular risk factors. In this article it is compared the effects of rimonabant treatment in obese patients with cardiovascular risk factors to usual obesity pharmacological treatment. BioMed Central 2009-10-16 /pmc/articles/PMC2770455/ /pubmed/19835615 http://dx.doi.org/10.1186/1758-5996-1-18 Text en Copyright © 2009 Murro; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Murro, Ada Letícia B
The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant
title The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant
title_full The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant
title_fullStr The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant
title_full_unstemmed The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant
title_short The endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant
title_sort endocanabinnoid system and diabetes - critical analyses of studies conducted with rimonabant
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770455/
https://www.ncbi.nlm.nih.gov/pubmed/19835615
http://dx.doi.org/10.1186/1758-5996-1-18
work_keys_str_mv AT murroadaleticiab theendocanabinnoidsystemanddiabetescriticalanalysesofstudiesconductedwithrimonabant
AT murroadaleticiab endocanabinnoidsystemanddiabetescriticalanalysesofstudiesconductedwithrimonabant

Ejemplares similares